Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | Olutasidenib |
| Trade Name | Rezlidhia |
| Synonyms | FT-2102 |
| Drug Descriptions |
Rezlidhia (olutasidenib) targets IDH1 R132 mutations, leading to decreased 2HG production and potentially promoting differentiation and decreasing proliferation of IDH R132-mutant cancer cells (PMID: 31971798). Rezlidhia (olutasidenib) is FDA approved for use in adult patients with relapsed or refractory acute myeloid leukemia with a susceptible IDH1 mutation (FDA.gov). |
| DrugClasses | IDH1 Inhibitor 8 |
| CAS Registry Number | 1887014-12-1 |
| NCIT ID | C129687 |